TI
ALNY icon

Trexquant Investment’s Alnylam Pharmaceuticals ALNY Stock Holding History

Trexquant Investment’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5M Sell
48,197
-13,563
-22% -$4.09M 0.09% 296
2026
Q1 		$20.4M Buy
61,760
+35,019
+131% +$11.9M 0.15% 148
2025
Q4 		$10.6M Buy
26,741
+14,345
+116% +$6.35M 0.09% 291
2025
Q3 		$5.65M Sell
12,396
-8,147
-40% -$3.32M 0.06% 504
2025
Q2 		$6.7M Buy
+20,543
New +$5.68M 0.08% 413
2025
Q1 		– Sell
-44,024
Closed -$10.4M – 1525
2024
Q4 		$10.4M Sell
44,024
-46,719
-51% -$12.3M 0.12% 251
2024
Q3 		$25M Buy
90,743
+52,880
+140% +$13.8M 0.32% 54
2024
Q2 		$9.2M Sell
37,863
-59,112
-61% -$9.33M 0.14% 211
2024
Q1 		$14.5M Buy
96,975
+45,578
+89% +$7.6M 0.29% 54
2023
Q4 		$9.84M Buy
51,397
+40,376
+366% +$6.88M 0.22% 109
2023
Q3 		$1.95M Buy
+11,021
New +$2.1M 0.05% 496
2023
Q1 		– Sell
-43,673
Closed -$10.4M – 1409
2022
Q4 		$10.4M Buy
43,673
+561
+1% +$120K 0.29% 81
2022
Q3 		$8.63M Buy
+43,112
New +$8.22M 0.3% 73
2022
Q2 		– Sell
-21,496
Closed -$3.51M – 1487
2022
Q1 		$3.51M Buy
+21,496
New +$3.27M 0.16% 152
2021
Q1 		– Sell
-6,393
Closed -$831K – 1092
2020
Q4 		$831K Buy
+6,393
New +$854K 0.09% 301
2020
Q2 		– Sell
-16,471
Closed -$1.79M – 1146
2020
Q1 		$1.79M Buy
16,471
+10,522
+177% +$1.21M 0.13% 238
2019
Q4 		$685K Buy
5,949
+214
+4% +$21.3K 0.04% 469
2019
Q3 		$461K Sell
5,735
-8,858
-61% -$701K 0.04% 472
2019
Q2 		$1.06M Buy
14,593
+4,513
+45% +$346K 0.1% 297
2019
Q1 		$942K Buy
+10,080
New +$843K 0.07% 415
2018
Q1 		– Sell
-3,021
Closed -$384K – 1043
2017
Q4 		$384K Buy
+3,021
New +$380K 0.04% 625
2015
Q4 		– Sell
-27,859
Closed -$2.24M – 985
2015
Q3 		$2.24M Buy
+27,859
New +$3.1M 0.19% 126

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trexquant Investment's ALNY Position: Q2 2026 in Review

Trexquant Investment reduced its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q2 2026, selling an estimated $4.09M and leaving 48,197 shares worth $14.5M. The position accounts for 0.09% of the portfolio, ranked #296.

Trexquant Investment first reported a position in ALNY in Q3 2015 and has held it in 22 quarters since. The position peaked at $25M in Q3 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Trexquant Investment held 48,197 shares of Alnylam Pharmaceuticals worth $14.5M as of Q2 2026.
  • Trexquant Investment sold 13,563 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.09M.
  • Alnylam Pharmaceuticals made up 0.09% of Trexquant Investment's portfolio in Q2 2026, its #296 holding.
  • Trexquant Investment first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 22 quarters since.
  • Trexquant Investment's Alnylam Pharmaceuticals position peaked at $25M in Q3 2024.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.